<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75583">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01955044</url>
  </required_header>
  <id_info>
    <org_study_id>MJN 8662</org_study_id>
    <nct_id>NCT01955044</nct_id>
  </id_info>
  <brief_title>PUFA Supplementation in Premature Infants</brief_title>
  <official_title>Early DHA Supplementation in Extremely Low Birth Weight Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NorthShore University HealthSystem Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ann &amp; Robert H Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Feinberg School of Medicine, Northwestern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mead Johnson Nutrition</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NorthShore University HealthSystem Research Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if buccal administration of a concentrated
      formulation of long-chain polyunsaturated fatty acids (LCPUFA) can help to maintain
      docosahexaenoic acid (DHA) levels in extremely low birth weight (ELBW) infants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a multi-center, randomized, placebo controlled, double blind trial.

      Two doses of PUFA will be compared to placebo- a &quot;high&quot; dose and a &quot;low&quot; dose.

      ELBW infants will be enrolled into this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>long-chain polyunsaturated fatty acid (LCPUFA) levels</measure>
    <time_frame>2 weeks of life</time_frame>
    <safety_issue>No</safety_issue>
    <description>LCPUFA levels will be measured at 2 weeks of life.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>LCPUFA levels</measure>
    <time_frame>8 weeks of life</time_frame>
    <safety_issue>No</safety_issue>
    <description>LCPUFA levels will be measured at 8 weeks of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resolvin levels</measure>
    <time_frame>8 weeks of life</time_frame>
    <safety_issue>No</safety_issue>
    <description>Resolvin, a metabolite of LCPUFA, will be measured at 8 weeks of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resolvin levels</measure>
    <time_frame>2 weeks of life</time_frame>
    <safety_issue>No</safety_issue>
    <description>resolvin, a metabolite of LCPUFA, will be measured at 2 weeks of life.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Premature, Extremely Low Birth Weight Infants</condition>
  <condition>Polyunsaturated Fatty Acid Levels</condition>
  <arm_group>
    <arm_group_label>&quot;high&quot; dose LCPUFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the &quot;high&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>&quot;low&quot; dose LCPUFA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>the &quot;low&quot; dose LCPUFA supplement is a drop that will be administered to ELBW infants.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the &quot;placebo&quot; is a drop that will be administered to ELBW infants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>LCPUFA supplement</intervention_name>
    <arm_group_label>&quot;high&quot; dose LCPUFA</arm_group_label>
    <arm_group_label>&quot;low&quot; dose LCPUFA</arm_group_label>
    <other_name>PUFA supplement</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a) Premature infant born at gestational age less than 34 weeks

          -  b) Birth weight less than 1000 grams

          -  c) Legally authorized representative is able to provide written informed consent
             within the first 72 hours of life, prior to the performance of an protocol-specified
             evaluations or procedures

        Exclusion Criteria:

          -  a) infants with known metabolic disorder

          -  b) infants with known congenital gastrointestinal anomaly

          -  c) infants who are deemed to be inappropriate for enrollment per attending
             neonatologist
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>72 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S Caplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NorthShore University HealthSystem</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brandy L Frost, MD</last_name>
    <phone>847-570-2033</phone>
    <email>bfrost@northshore.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael S Caplan, MD</last_name>
    <phone>847-570-2530</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel T Robinson, MD</last_name>
      <phone>312-227-4190</phone>
      <email>dtrobinson@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Daniel T Robinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Prentice Women's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel T Robinson, MD</last_name>
      <phone>312-227-4190</phone>
    </contact>
    <investigator>
      <last_name>Daniel T Robinson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University HealthSystem</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy L Frost, MD</last_name>
      <phone>847-570-2033</phone>
      <email>bfrost@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Brandy L Frost, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 8, 2014</lastchanged_date>
  <firstreceived_date>September 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>NorthShore University HealthSystem Research Institute</investigator_affiliation>
    <investigator_full_name>Brandy Frost</investigator_full_name>
    <investigator_title>Attending Neonatologist, Clinician Educator</investigator_title>
  </responsible_party>
  <keyword>neonatal prematurity</keyword>
  <keyword>infant, extremely low birth weight</keyword>
  <keyword>fatty acids, polyunsaturated</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Birth Weight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
